Trial aims to find best way to stop powerful arthritis drug, reduce costs and side effects
NCT ID NCT06037460
Summary
This study is for people with giant cell arteritis, an inflammatory blood vessel disease, who have been in remission for at least 12 weeks while taking the drug tocilizumab. It compares two methods for stopping the medication: quitting immediately versus a slow, gradual reduction. The main goal is to see which approach better keeps the disease from coming back, while also tracking side effects and quality of life for the 120 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chu Dijon Bourgogne
Dijon, 21000, France
Conditions
Explore the condition pages connected to this study.